Tuesday, March 11, 2025 5:02:47 PM
mani,
You’re actually highlighting the beauty of the Roswell deal—time…
The most exciting aspect of acquiring the Roswell DC platform is that we are already years into its development and clinical investigation as a combo agent. When the NWBO press release was published, we were already in PII which took years to achieve!
When the news quoted and linked below was first published in 2020, the ongoing DC trials had not even started yet. Today, we know that the Phase I Roswell trials were successful and advanced to Phase II, with funding that includes peer-reviewed U.S. government grants.
The trials at Roswell resulted from peer-reviewed research that also took years …NWBO was quite fortunate to acquire the Roswell DC platform at Phase II, and those trials involve more than one distinct type of cancer too!
“Our approach overcame both primary, or initial, and acquired resistance, and we also saw evidence of tumor-specific systemic immunological memory, suggesting that this strategy may generate long-term anticancer responses even against hard-to-treat melanoma and breast tumors.”
https://www.broadcastmed.com/cancer/9753/news/new-roswell-park-strategy-for-overcoming-resistance-to-immunotherapy-unleashes-power-of-dendritic-cells
https://www.nature.com/articles/s41467-020-19192-z
Jump ahead a few YEARS from that 2020 headline and see where we are now with the Roswell DC platform …
https://clinicaltrials.gov/study/NCT04348747?a=15&b=29
https://clinicaltrials.gov/study/NCT04093323?a=39
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
You’re actually highlighting the beauty of the Roswell deal—time…
The most exciting aspect of acquiring the Roswell DC platform is that we are already years into its development and clinical investigation as a combo agent. When the NWBO press release was published, we were already in PII which took years to achieve!
When the news quoted and linked below was first published in 2020, the ongoing DC trials had not even started yet. Today, we know that the Phase I Roswell trials were successful and advanced to Phase II, with funding that includes peer-reviewed U.S. government grants.
The trials at Roswell resulted from peer-reviewed research that also took years …NWBO was quite fortunate to acquire the Roswell DC platform at Phase II, and those trials involve more than one distinct type of cancer too!
“Our approach overcame both primary, or initial, and acquired resistance, and we also saw evidence of tumor-specific systemic immunological memory, suggesting that this strategy may generate long-term anticancer responses even against hard-to-treat melanoma and breast tumors.”
https://www.broadcastmed.com/cancer/9753/news/new-roswell-park-strategy-for-overcoming-resistance-to-immunotherapy-unleashes-power-of-dendritic-cells
https://www.nature.com/articles/s41467-020-19192-z
Jump ahead a few YEARS from that 2020 headline and see where we are now with the Roswell DC platform …
https://clinicaltrials.gov/study/NCT04348747?a=15&b=29
https://clinicaltrials.gov/study/NCT04093323?a=39
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
